| Withdrawn | Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia NCT06015750 | Alexion Pharmaceuticals, Inc. | Phase 4 |
| Recruiting | The Effect of Monoallelic Variants in the ALPL Gene on the Natural Course of Hypophosphatasia in Russia NCT07390240 | AstraZeneca | — |
| Recruiting | Characteristics of Hypophosphatasia in Adult Patients in Rheumatology and Their Value in Developing an Algorit NCT06574282 | University of Bonn | — |
| Active Not Recruiting | Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP NCT06079359 | Alexion Pharmaceuticals, Inc. | Phase 3 |
| Active Not Recruiting | Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa NCT06079372 | Alexion Pharmaceuticals, Inc. | Phase 3 |
| Active Not Recruiting | Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously NCT06079281 | Alexion Pharmaceuticals, Inc. | Phase 3 |
| Completed | Pilot Trial of Single Dose Ilofotase Alfa in Hypophosphatasia NCT05890794 | AM-Pharma | Phase 1 / Phase 2 |
| Recruiting | Prospective, Longitudinal, Observational Registry of Adult Patients With Hypophosphatasia (REG-HYPO) NCT05596539 | Assistance Publique - Hôpitaux de Paris | — |
| Unknown | Characteristics of Hypophosphatasia in Adult Patients in Rheumatology NCT06161142 | University of Bonn | — |
| Recruiting | A Prospective Sub-Study of the Global Hypophosphatasia Registry NCT05234567 | Alexion Pharmaceuticals, Inc. | — |
| Completed | Study of ALXN1850 in Participants With Hypophosphatasia (HPP) NCT04980248 | Alexion Pharmaceuticals, Inc. | Phase 1 |
| Active Not Recruiting | United States Hypophosphatasia Molecular Research Center NCT05062629 | Children's Mercy Hospital Kansas City | — |
| Unknown | The PORTRAIT Study NCT04222452 | Sheffield Teaching Hospitals NHS Foundation Trust | — |
| Completed | Unraveling Genetics of HypoPhosPhatasia (HPP Genetics) NCT04925804 | CENTOGENE GmbH Rostock | — |
| Withdrawn | Relieving Burden of Hypophosphatasia in Adults With Functional Impairment Due to Chronic Disease NCT04189315 | Alexion Pharmaceuticals, Inc. | Phase 4 |
| Completed | Patient Reported Outcomes in Adults With Pediatric-onset Hypophosphatasia Treated With Strensiq® (Asfotase Alf NCT04195763 | Alexion Pharmaceuticals, Inc. | — |
| Enrolling By Invitation | Early Check: Expanded Screening in Newborns NCT03655223 | RTI International | — |
| Completed | Evaluate and Monitor Physical Performance of Adults Treated With Asfotase Alfa for Hypophosphatasia NCT03418389 | Dr. Lothar Seefried | — |
| Unknown | Circulating miRNAs and Bone Microstructure in Adults With Hypophosphatasia NCT04018287 | Medical University of Vienna | — |
| Completed | Health Burden of Hypophosphatasia NCT02751801 | Sheffield Teaching Hospitals NHS Foundation Trust | — |
| Completed | Characterisation of Adult-Onset Hypophosphatasia NCT02796885 | Sheffield Teaching Hospitals NHS Foundation Trust | — |
| Completed | Pharmacokinetic and Dose Response Study of Asfotase Alfa in Adult Patients With Pediatric-Onset Hypophosphatas NCT02797821 | Alexion Pharmaceuticals, Inc. | Phase 2 |
| Completed | Post-approval Clinical Study of Asfotase Alfa Treatment for Patients With Hypophosphatasia (HPP) in Japan NCT02531867 | Alexion Pharmaceuticals, Inc. | Phase 4 |
| Completed | Burden of Disease in Hypophosphatasia (HPP) NCT02291497 | Wuerzburg University Hospital | — |
| Recruiting | Natural History Study of Patients With Hypophosphatasia (HPP) NCT02237625 | Duke University | — |
| Completed | Safety and Efficacy of Asfotase Alfa in Patients With Hypophosphatasia (HPP) NCT02456038 | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | Phase 2 |
| Completed | Non-interventional Substudy of ALX-HPP-502 to Assess Natural History of Patients With Juvenile-onset HPP Who S NCT02235493 | Alexion Pharmaceuticals, Inc. | — |
| Completed | Dose Escalation Study to Evaluate the Safety and Tolerability of Multiple Infusions of BPS804 in Adults With H NCT01406977 | Ultragenyx Pharmaceutical Inc | Phase 2 |
| Completed | Open-Label Study of Asfotase Alfa in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP) NCT01176266 | Alexion Pharmaceuticals, Inc. | Phase 2 / Phase 3 |
| Recruiting | Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford NCT01793168 | Sanford Health | — |
| Completed | Safety and Efficacy Study of Asfotase Alfa in Adolescents and Adults With Hypophosphatasia (HPP) NCT01163149 | Alexion Pharmaceuticals, Inc. | Phase 2 |
| Withdrawn | Safety and Efficacy Study of ENB-0040 in Juvenile Patients With Hypophosphatasia (HPP) NCT00894075 | Alexion Pharmaceuticals, Inc. | Phase 2 |
| Completed | Extension Study of Protocol ENB-002-08 - Study of Asfotase Alfa in Infants and Young Children With Hypophospha NCT01205152 | Alexion Pharmaceuticals, Inc. | Phase 2 |
| Approved For Marketing | Expanded Access Program for Asfotase Alfa Treatment for Patients With Infantile- or Juvenile-onset Hypophospha NCT02496689 | Alexion Pharmaceuticals, Inc. | — |